Asiatic-European association of ozone therapists

Peretiagina N.S., Kachalina T.S., Grechkanyov G.O.,Russian Association of Ozone Therapy, Nizhny Novgorod, Russia( medexport@sandy.ru

Abstract Acute inflammatory processes of female genital organs cause, in a great number of cases, serious problems in menstrual, sexual and reproductive functions and are marked by long and current relapses. They are accompanied by the following clinical features: increase of microflora resistance to antibiotics, appearance of medical intolerance, that essentially reduces the efficiency of standard methods of treatment. It results in high frequency (up to 76,6 %) of chronic non-specific inflammatory processes in internal genital organs.
There were 37 patients with uterus and appendages inflammatory diseases, under control, who along with traditional therapy were treated with 8 to 10 infusions of 0.9 % ozonized physiological solution with an ozone concentration of 3000 g/L.At the same time, in the control group 15 patients received only traditional antibacterial, sedative, desensibilizing therapy and vitamins. It was shown that, at the given category of patients, infusions of ozonized solution plus the traditional treatment, positively influenced the biochemical and cytological parameters of blood, albumin and lipid exchange, endogen intoxication and coagulation ability of bloodOn the background of local inflammatory process subsiding the patients had the increase of curtailing time and bleeding, decrease in activity of plasma procoagulants, protrombin index and fibrinogen. Some parameters of endogen intoxication were simultaneously reduced: the level of lipid peroxidation, malonic dialdehyde, the level of middle peptides, bilirubin, creatinin.Positive influence of ozone therapy on the albumin synthesis of liver function is revealed. Application of ozone in the complex therapy of inflammatory diseases of female genital organs allows to improve the treatment results, to diminished the frequency of complications and to reduce the time of treatment.

Castillo P. and Salas T. (Cuba)The cerebrovascular disease is one of the main problems in medical practice, because of the high tendency to produce sequels in those who survive, limiting their physical capacities. The purpose of this study was to evaluate the effectiveness of ozone therapy in the ischemic cerebrovascular disease, in acute phase. One hundred patients, with this diagnosis, that attended the Neurological Institute during a period of one year, were evaluated. Ozone by rectal insufflation was daily administered (at an ozone concentration of 40 mg/L and 200 mL), for a total of 15 sessions. These patients were evaluated by clinical examination, blood test and their validity through the multidimensional evaluation method, at the beginning and at the end of the treatment. Antiaggregant medication was associated. The clinical stage improved in 80 % of patients treated with ozone therapy, with a satisfactory increase of their quality of life.

Food and Drug Administration, HH

The Food and Drug Administration (FDA) is amending its regulation on the use of ozone-depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for albuterol used in oral pressurized metered-dose inhalers (MDIs). Under the Clean Air Act, FDA, in consultation with the Environmental Protection Agency (EPA), is required to determine whether an FDA-regulated product that releases an ODS is an essential use of the ODS. Two albuterol MDIs that do not use an ODS have been marketed for more than 3 years. FDA has determined that the two non-ODS MDIs will be satisfactory alternatives to albuterol MDIs containing ODSs and is removing the essential-use designation for albuterol MDIs as of December 31, 2008. Albuterol MDIs containing an ODS cannot be marketed after this date.